Economic burden of some age-related diseases

Background. One of the main concerns posed by implementing new biomedical technologies is the lack of a pharmacoeconomic justification for the economic effect or the burden of certain nosologies on the state budget. To date, the medical literature on age-related diseases focuses on diagnosis, pathogenesis, new methods of treatment and the results of prescribed treatment. However, assessing the economic burden of these diseases is equally important. Only for selected diseases, regular publications on the calculation of the economic effect and economic burden of diseases can be found. For less common diseases, there are single publications, the information from which is no longer relevant and requires regular updating and maintenance.Aim. To conduct an indicative assessment of the economic burden for the most common age-related diseases.Materials and methods. When preparing the publication, foreign and domestic sources containing economic information about the most common age-associated diseases were used.Annual reports of biopharmaceutical companies producing drugs for the treatment of age-related diseases were used to obtain an understanding of current developments in the treatment of these diseases. Additionally, data from Rosreestr (Russian Federal Service for State Registration, Cadastre and Cartography) were used for certain diseases.Results. According to the analyzed information, it has been found that age-related diseases are a significant economic burden for the healthcare system of the state. However, not all specialized medical organizations assess the economic burden associated with such diseases.Conclusion. As a result of analyzing the economic burden of the most common age-related diseases, the conclusion can be drawn that regular assessment of the economic burden for Alzheimer's disease, diabetes, chronic obstructive pulmonary disease, depression, atherosclerosis and osteoporosis is necessary